Skip to main content
Top
Published in: Nuclear Medicine and Molecular Imaging 1/2020

01-02-2020 | Prostate Cancer | Case Report

Isolated Hepatic Metastasis of Prostate Cancer with Variable 18F-fluociclovine Uptake by PET/CT Imaging

Authors: Endel Sorra, Muhammad U. Aziz, Fangyu Peng

Published in: Nuclear Medicine and Molecular Imaging | Issue 1/2020

Login to get access

Abstract

A 74-year-old man presented with rapid rising prostate-specific antigen (PSA) 2 years after treatment of prostate cancer with prostatectomy and salvage radiation therapy. PSA increased from 923 to 4349 ng/mL within 2 months. No osseous metastatic lesions of prostate cancer were detected by 18F-sodium fluoride PET/CT imaging at an outside facility. 18F-fluciclovine PET/CT imaging was performed to evaluate local recurrence of prostate cancer at surgical bed of prostatectomy and distant metastasis. One small focus of low-level 18F-fluciclovine radiotracer uptake was noted in the surgical bed of prostatectomy without corresponding soft tissue mass on CT. No fluciclovine-avid lymph nodes or osseous metastatic lesions were detected, but multiple hypodense lesions of variable 18F-fluciclovine radiotracer uptake were noted in the liver, concerning for isolated liver metastasis of prostate cancer. The patient underwent docetaxel chemotherapy for treatment of prostate cancer liver metastasis and showed a favorable response to treatment by significant decreased size of the hypodense lesions in the liver on post treatment abdominal CT, along with dramatic reduction of PSA level and improvement of liver function. The findings from this case highlight the importance of checking hypoattenuating lesions in the liver for the presence of prostate cancer metastatic lesions that might appear similar to other benign hypoattenuating lesions of low fluciclovine uptake relative to physiological 18F-fluciclovine uptake in the normal liver tissues, a potential pitfall at interpretation of 18F-fluociclovine PET/CT imaging.
Literature
1.
go back to reference Sakata T, Ferdous G, Tsuruta T, Satoh T, Baba S, Muto T, et al. L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int. 2009;59:7–18.CrossRef Sakata T, Ferdous G, Tsuruta T, Satoh T, Baba S, Muto T, et al. L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int. 2009;59:7–18.CrossRef
2.
go back to reference Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432–5.PubMed Jager PL, Vaalburg W, Pruim J, de Vries EG, Langen KJ, Piers DA. Radiolabeled amino acids: basic aspects and clinical applications in oncology. J Nucl Med. 2001;42:432–5.PubMed
3.
go back to reference Oka S, Hattori R, Kurosaki F, Toyama M, Williams LA, Yu W, et al. A preliminary study of anti-1-amino-3-18F fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J Nucl Med. 2007;48:46–55.PubMed Oka S, Hattori R, Kurosaki F, Toyama M, Williams LA, Yu W, et al. A preliminary study of anti-1-amino-3-18F fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J Nucl Med. 2007;48:46–55.PubMed
4.
go back to reference Schuster DM, Votaw JR, Nieh PT, Yu W, Nye JA, Master V, et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluororacyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48:56–63.PubMed Schuster DM, Votaw JR, Nieh PT, Yu W, Nye JA, Master V, et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluororacyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48:56–63.PubMed
5.
go back to reference Schuster DM, Nanni C, Fanti S, Oka S, Okudaira H, Inoue Y, et al. Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. J Nucl Med. 2014;55:1986–92.CrossRef Schuster DM, Nanni C, Fanti S, Oka S, Okudaira H, Inoue Y, et al. Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. J Nucl Med. 2014;55:1986–92.CrossRef
6.
go back to reference Parent EE, Schuster DM. Update on 18F-fluciclovine PET for prostate cancer imaging. J Nucl Med. 2018;59:733–9.CrossRef Parent EE, Schuster DM. Update on 18F-fluciclovine PET for prostate cancer imaging. J Nucl Med. 2018;59:733–9.CrossRef
7.
go back to reference Gusman M, Aminsharifi JA, Peacock JG, Anderson SB, Clemenshaw MN, Banks KP. Review of 18F-fluciclovine PET for detection of recurrent prostate cancer. Radiographics. 2019;39:822–41.CrossRef Gusman M, Aminsharifi JA, Peacock JG, Anderson SB, Clemenshaw MN, Banks KP. Review of 18F-fluciclovine PET for detection of recurrent prostate cancer. Radiographics. 2019;39:822–41.CrossRef
8.
go back to reference Pouessel D, Gallet B, Bibeau F, Avancès C, Iborra F, Sénesse P, et al. Liver metastases in prostate carcinoma: clinical characteristics and outcome. BJU Int. 2007;99:807–11.CrossRef Pouessel D, Gallet B, Bibeau F, Avancès C, Iborra F, Sénesse P, et al. Liver metastases in prostate carcinoma: clinical characteristics and outcome. BJU Int. 2007;99:807–11.CrossRef
9.
go back to reference Attila T, Datta MW, Sudakoff G, Abu-Hajir M, Massey BT. Intrahepatic portal hypertension secondary to metastatic carcinoma of the prostate. WMJ. 2007;106:34–6.PubMed Attila T, Datta MW, Sudakoff G, Abu-Hajir M, Massey BT. Intrahepatic portal hypertension secondary to metastatic carcinoma of the prostate. WMJ. 2007;106:34–6.PubMed
10.
go back to reference Wang H, Li B, Zhang P, Yao Y, Chang J. Clinical characteristics and prognostic factors of prostate cancer with liver metastases. Tumor Biol. 2014;35:595–601.CrossRef Wang H, Li B, Zhang P, Yao Y, Chang J. Clinical characteristics and prognostic factors of prostate cancer with liver metastases. Tumor Biol. 2014;35:595–601.CrossRef
11.
go back to reference Wang SC, McCarthy LP, Mehdi S. Isolated hepatic metastasis from prostate carcinoma. Urol Case Rep. 2016;10:51–3.CrossRef Wang SC, McCarthy LP, Mehdi S. Isolated hepatic metastasis from prostate carcinoma. Urol Case Rep. 2016;10:51–3.CrossRef
12.
go back to reference Kawai H, Shiba H, Kanehira M, Sakamoto T, Furukawa K, Yanaga K. Successful resection of a solitary metastatic liver tumor from prostate cancer 15 years after radical prostatectomy: a case report. Surg Case Rep. 2017;3:17.CrossRef Kawai H, Shiba H, Kanehira M, Sakamoto T, Furukawa K, Yanaga K. Successful resection of a solitary metastatic liver tumor from prostate cancer 15 years after radical prostatectomy: a case report. Surg Case Rep. 2017;3:17.CrossRef
13.
go back to reference Iyamu I, Wachsmann J, Truelson J, Mathews D, Peng F. Detection of widespread metastasis in a case of aggressive carcinoma showing thymuslike differentiation (CASTLE Disease) using 18F-FDG PET/CT. Clin Nucl Med. 2015;40:689–91.CrossRef Iyamu I, Wachsmann J, Truelson J, Mathews D, Peng F. Detection of widespread metastasis in a case of aggressive carcinoma showing thymuslike differentiation (CASTLE Disease) using 18F-FDG PET/CT. Clin Nucl Med. 2015;40:689–91.CrossRef
14.
go back to reference Savir-Baruch B, Banks KP, McConathy JE, Molchanova-Cook OP, Parent EE, Takalkar A, et al. ACR-ACNM practice parameter for the performance of fluorine-18 fluciclovine-PET/CT for recurrent prostate cancer. Clin Nucl Med. 2018;43:909–17.CrossRef Savir-Baruch B, Banks KP, McConathy JE, Molchanova-Cook OP, Parent EE, Takalkar A, et al. ACR-ACNM practice parameter for the performance of fluorine-18 fluciclovine-PET/CT for recurrent prostate cancer. Clin Nucl Med. 2018;43:909–17.CrossRef
15.
go back to reference Singh A, Cheedella NKS, Shakil SA, Gulmi F, Kim DS, Wang JC. Liver metastases in prostate carcinoma represent a relatively aggressive subtype refractory to hormonal therapy and short-duration response to docetaxel monotherapy. World J Oncol. 2015;6:265–9.CrossRef Singh A, Cheedella NKS, Shakil SA, Gulmi F, Kim DS, Wang JC. Liver metastases in prostate carcinoma represent a relatively aggressive subtype refractory to hormonal therapy and short-duration response to docetaxel monotherapy. World J Oncol. 2015;6:265–9.CrossRef
16.
go back to reference Andriole GL, Kostakoglu L, Chau A, Duan F, Mahmood U, Mankoff DA, et al. The impact of positron emission tomography with 18F- fluciclovine on the management of patients with biochemical recurrence of prostate cancer: results from the LOCATE trial. J. Urol. 2019;201:322–31.CrossRef Andriole GL, Kostakoglu L, Chau A, Duan F, Mahmood U, Mankoff DA, et al. The impact of positron emission tomography with 18F- fluciclovine on the management of patients with biochemical recurrence of prostate cancer: results from the LOCATE trial. J. Urol. 2019;201:322–31.CrossRef
Metadata
Title
Isolated Hepatic Metastasis of Prostate Cancer with Variable 18F-fluociclovine Uptake by PET/CT Imaging
Authors
Endel Sorra
Muhammad U. Aziz
Fangyu Peng
Publication date
01-02-2020
Publisher
Springer Singapore
Published in
Nuclear Medicine and Molecular Imaging / Issue 1/2020
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-019-00623-9

Other articles of this Issue 1/2020

Nuclear Medicine and Molecular Imaging 1/2020 Go to the issue